Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2015 and provide a corporate update beginning at 5:00 pm Eastern Time on Tuesday, February 16, 2016 / 09:00 am Australian Eastern Daylight Time on Wednesday, February 17, 2016.
To access the call, dial 877-456-0438 (toll-free US), 1800-005-989 (toll-free Australia) or 262-558-6163 (outside of the US). The passcode is 49888069. The conference call will be accompanied by a slide presentation. Please log in approximately 10 minutes prior to the scheduled start time. The live webcast can be accessed by clicking here.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Mesoblast website, which can be accessed by clicking here.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact: Michael Schuster Head, Investor Relations Mesoblast Limited T: 212-880-2060 E: [email protected] Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected]
